Cargando…

New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53

BACKGROUND: p53 is a transcription factor with tumour suppressor properties, which is able to induce mitochondrial apoptosis independently of its transcriptional activity. We recently synthesised two new compounds (ISA27 and SM13), which block p53-MDM2 interaction and induce apoptosis in p53 wild-ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorriento, D, Del Giudice, C, Bertamino, A, Ciccarelli, M, Gomez-Monterrey, I, Campiglia, P, Novellino, E, Illario, M, Trimarco, B, De Luca, N, Iaccarino, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453617/ https://www.ncbi.nlm.nih.gov/pubmed/25422906 http://dx.doi.org/10.1038/bjc.2014.577

Ejemplares similares

Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
por: Costa, Barbara, et al.
Publicado: (2013)

Trafficking GRK2: Cellular and Metabolic consequences of GRK2 subcellular localization.
por: Sorriento, Daniela, et al.
Publicado: (2014)

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
por: Gibert, B, et al.
Publicado: (2012)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

Targeting the CaMKII/ERK Interaction in the Heart Prevents Cardiac Hypertrophy
por: Cipolletta, Ersilia, et al.
Publicado: (2015)

The Amino-Terminal Domain of GRK5 Inhibits Cardiac Hypertrophy through the Regulation of Calcium-Calmodulin Dependent Transcription Factors
por: Sorriento, Daniela, et al.
Publicado: (2018)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Combination therapy with PEG-IFN-α and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53
por: Hagiwara, S, et al.
Publicado: (2007)

Exploiting GRK2 Inhibition as a Therapeutic Option in Experimental Cancer Treatment: Role of p53-Induced Mitochondrial Apoptosis
por: Gambardella, Jessica, et al.
Publicado: (2020)

γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules
por: Prasad, Sahdeo, et al.
Publicado: (2016)

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
por: Canner, J A, et al.
Publicado: (2009)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

p53 mutation, deprivation and poor prognosis in primary breast cancer
por: Baker, L, et al.
Publicado: (2010)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
por: Lammers, T, et al.
Publicado: (2008)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
por: Cemazar, M, et al.
Publicado: (2005)

Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI
por: Gambarota, G, et al.
Publicado: (2008)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l4auhrej8hfqeppiourlgp4tne